Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DGX stock price vs DHR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Needs Annual EPS, DHR P/E.
Implied fair value · at DGX's multiple
Needs Annual EPS, DGX P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
QUEST DIAGNOSTICS INC · implied price per share
Reporting currency could not be verified.
DANAHER CORP /DE/ · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
DGX · not enough data.
DHR · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
ABBOTT LABORATORIES
DGX vs ABT
THERMO FISHER SCIENTIFIC INC.
DGX vs TMO
HCA Healthcare, Inc.
DGX vs HCA
LABCORP HOLDINGS INC.
DGX vs LH
WEST PHARMACEUTICAL SERVICES INC
DGX vs WST
AGILENT TECHNOLOGIES, INC.
DGX vs A
ILLUMINA, INC.
DGX vs ILMN
JOHNSON & JOHNSON
DGX vs JNJ
LOEWS CORP
DGX vs L
BERKSHIRE HATHAWAY INC
DGX vs BRK-B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DGX can sustain its faster growth and preserve its stronger ROIC while closing some of the margin gap versus DHR, then DGX can work as a relative value buy because it trades at a clear multiple discount; otherwise, DHR’s superior profitability and cleaner leverage profile justify its premium.
DGX trades at a meaningful valuation discount to DHR on P/E, P/S, EV/EBITDA, and EV/Revenue, which supports a lower implied value for DHR-comparison framework. However, DGX also has faster revenue growth, so the discount appears to reflect quality and margin differences more than growth alone.
Supporting Metrics
